Kornimate/medical-research-clean huggingface dataset:
cmr versus ct in coronary artery disease

Conditions: Coronary Artery Disease

Summary: concord is a prospective observational study evaluating the diagnostic accuracy of cardiovascular magnetic resonance (cmr) and computed tomography with fractional flow reserve (ct-ffr) in patients with suspected coronary artery disease, using invasive fractional flow reserve (ffr) as the reference standard.

in patients with suspected coronary artery disease (cad), ct coronary angiography (ctca) provides excellent sensitivity and negative predictive value, enabling the safe exclusion of significant cad. however, its positive predictive value remains suboptimal (c.50%). undertaking additional ct-ffr improves specificity and positive predictive value, reducing unnecessary invasive coronary angiography. it has been established that cmr perfusion imaging offers excellent diagnostic accuracy for the identification of functionally significant coronary artery disease. the diagnostic performance of qualitative cmr perfusion assessment may be further enhanced by additional quantitative assessment. the purpose of this prospective observational study is to evaluate the diagnostic performance of all three modalities (ct-ffr and qualitative and quantitative cmr perfusion imaging), involving 300 patients with suspected coronary artery disease referred for invasive coronary angiography. a subset of 167 subjects will undergo an additional accelerated cmr scan for comparison. invasively measured fractional flow reserve (ffr) will serve as the reference standard.

Eligibility criteria:
inclusion criteria: * patients aged ≥18 years * referred for invasive coronary angiography for investigation of chest pain exclusion criteria: * recent acute coronary syndrome (\< 6 months) * previous coronary artery bypass grafting * severe claustrophobia * absolute contraindications to cmr - those with mr conditional or safe devices will be included * second-/third-degree atrioventricular block * severe chronic obstructive pulmonary disease * moderate-severe asthma * estimated glomerular filtration rate \<30 ml/min/1.73m2 * women who are pregnant, breast-feeding or of child-bearing potential( premenopausal women) * contraindication to iodinated contrast * participation in a research study involving an investigational product in the past 12 weeks

Keywords: mri ct-ffr coronary artery disease
effect of different physical programs on the body composition of adult men and women with an initial body fat >25% and >30%, respectively.

Conditions: Overweight; Obesity

Summary: compare the effect of different physical programs on the body composition of adult women and men with a total body fat percentage ≥ 30 % at the beginning of the test or bmi ≥25

weight loss by exercise can be frequently deceptive. the focus continues to be centred around total body weight and body mass index (bmi), despite the fact that body fat and fat-free mass are the indicators that represent the greatest risk in the comorbidity associated with obesity. body weight per se cannot be considered to be reliable; however, its quality can be justified, when measured together with the loss in body fat and the maintenance or increase in fat-free mass. the purpose of the study is compare the effect of different physical programs (fa) on the body composition (bc) of adult women with a total body fat percentage ≥ 30 % and adult men with a bmi ≥25 at the beginning of the test. participants (n=220, women = 110, men = 110) will be recruited through outpatient from private clinics in cádiz, andalucía, spain, as well as through community presentations. overweight or obese and sedentary women and men will be randomly assigned into three groups according to different levels of af. 21 of the participants will be assigned to the sedentary control group (mets \ 6). for 6 months, all of the women shall follow the same diet with an identical distribution of macronutrients. there will be a weekly check up of weight, fat, body water and muscle mass for all of them.

Eligibility criteria:
inclusion criteria: * having a body fat percentage \>30 * having a bmi \>25 * being sedentary and * have not been submitted to a restrictive diet in the 6 months preceding this study. exclusion criteria: * suffered from type 2 diabetes or renal conditions * being pregnancy or attempt at pregnancy, * being in a maternal lactation period, * being underage * undergoing antidepressant pharmacological treatment

Keywords: obesity physical activity fat mass fat free mass
evaluation of surgical stress index (ssi) during sevoflurane/remifentanil anesthesia

Conditions: Analgesia

Summary: the aim of the present prospective randomized study was to challenge the ability of ssi to detect painful stimulation during sevoflurane - remifentanil anesthesia.

general anesthesia can be considered as a combination of hypnosis, antinociception and immobility. whereas monitoring of depth of hypnosis, and muscle relaxation can be regarded as accepted, determination of the nociception is based on clinical signs like somatic or autonomic responses. recently, the multivariate surgical stress index (ssi)has been demonstrated to correlate with surgical stress intensity. thus, ssi might be a useful variable to adjust analgesic drug administration in individual patients. we want to investigate whether ssi is able to indicate nociception following standardized noxious stimulation during balanced sevoflurane - remifentanil anesthesia.

Eligibility criteria:
inclusion criteria: * age between 18 and 65 years * asa physical status 1-2 * elective surgery in general anesthesia of 1 to 2 hours * written informed consent exclusion criteria: * pregnancy * history of cardiac arrhythmia * presence of any neuromuscular or neurological disease * use of cns-active medication or abuse of alcohol or illicit drugs

Keywords: anesthesia general anesthetics inhalation stress measurement surgical stress diagnostic techniques and procedures
association between molar-incisor hypomineralization, maternal stress and anxiety: a cross-sectional study.

Conditions: Molar Incisor Hypomineralization

Summary: this study aims to evaluate the association between molar-incisor hypomineralization, maternal stress and anxiety in a group of pediatric patients.

molar incisor hypomineralization is a medical global condition characterised by a qualitative defect in the enamel mineralization affecting the first permanent molar teeth predominantly, and with or without the involvement of incisor teeth. mih have various and major clinical challenges. clinically the lesion appears with well demarcated opacity and porous with a color that ranges from white, creamy or yellow to brownish. thus differ in its severity from mild to severe. the ohrqol is a fundamental part of our children's general health and well-being but with the condition mentioned above their eating, sleeping, social interaction, self-esteem is being minimized and so the analysis of the etiological factors should be carried out. worldwide the prevalence of this condition, mih was found to be from 2.4 to 40%, the reason behind this huge range difference is the use of different indices, diagnostic criteria, variability between examiners, lack of standardized methods of recording lesions and different age groups, while recent studies in egypt reported 2.3% of mih in a group of egyptian children from 8 to 12 years in cairo. moreover, 878 million people across the world were mih-affected and 17.5 million new cases are identified each year according to a study published 02 august 2022 in egypt. despite the worldwide increasing interest in the causes of mih, there is still insufficient evidence to verify the etiological factors of this condition, especially stress and anxiety. there is a potential relationship between stress and mih, as glucocorticoids mainly cortisol have receptors on ameloblasts and so further research and population-based studies are urgently required to evaluate the prevalence of mih and its association with stress.

Eligibility criteria:
inclusion criteria: * pediatric patients with completely erupted at least one first permanent molar with mih, based on a validated diagnostic criteria * children age range from 8 and 12 years * parents who agree and signed the consent for their children participation exclusion criteria: -enamel defects only limited to the permanent incisors; as the term mih was chosen to always highlight the fact that molars are involved regularly in this condition, opacities on incisors only may relate to another origin of the defect and should not be referred to as mih.
effect of short-term motilitone therapy on health-related quality of life in pd patients with gastrointestinal symptoms

Conditions: Parkinson Disease; Dyspepsia

Summary: the purpose of this study is to determine whether da-9701(motilitone) is effective and safe for the treatment on health-related quality of life in parkinson's disease (pd) patients with gastrointestinal symptoms.

gastrointestinal (gi) symptoms are frequently complained by pd patients. to improve their symptoms, prokinetics are often used in clinics. however, some prokinetics are dopamine receptor antagonist which can aggravate motor symptoms of pd patients or develop tardive dyskinesia when it affects dopamine receptors of the brain. da-9701 (motilitone) is recently developed herbal medication which has both 5-ht4 agonism and d2 antagonism. furthermore, it does not cross the blood brain barrier that can be safely used in pd patients. hypothetically it has a potential to be a good choice for the treatment of gi symptoms of pd patients. however, there has been no study that evaluates its efficacy and safety by randomized clinical trials in pd patients. this study will evaluate the efficacy and safety of da-9701 in the double-blind placebo-controlled phase 1 (4 weeks), and the long-term safety of da-9701 in the open-label phase 2 (8 weeks after phase 1).

Eligibility criteria:
inclusion criteria: * subjects were enrolled voluntarily and understood the contents of this clinical trial. * male or female parkinson disease (pd) patients between 50 and 80 years * subjects who had not received prokinetics (itopride, mosapride, corydalis tuber, levosulpiride, domperidone, etc.) at least 2 months prior to baseline visit * subjects complained at least one symptom of the following that suggests abnormal bowel functions: anorexia, nausea, abdominal distension, dyspepsia, early satiety, dysphagia, foreign body sensation associated with a meal, symptoms of gastroesophageal reflux, constipation, and defecation problem. exclusion criteria: * history of a gastrointestinal operation * subjects with active gastrointestinal diseases under treatment of gastroenterology within 1 month * existence of clinically significant cognitive decline or k-minimental status exam score 20 or less * subjects had depression or other psychiatric disorders treated with medications such as antidepressants or antipsychotics; mood tranquilizers, benzodiazepines, and sleep pills were permitted with fixed dose during a period of the clinical trial * subjects with severe active comorbidities which could interfere the quality of life of the patient * subjects with medical conditions which make difficult to be enrolled to the trial judged by clinicians * subjects with hypersensitivity or adverse event related to da-9701 (motilitone) * prior participation to other clinical trials within 3 months
physiotherapy and reaction time in hemophilia

Conditions: Hemophilia Arthropathy

Summary: this randomised controlled study was conducted to investigate the comprehensive physiotherapy combined with home exercises on individuals with hemophilic arthropathy in the lower extremity. there are two groups in the study: home exercises and comprehensive physiotherapy combined with home exercises. is physiotherapy combined with home exercises superior to home exercises on joint health, bleeding frequency, reaction time, dynamic balance, muscle strength? the aim of this study is to increase the compliance of hemophilic individuals to physiotherapy and adapt home exercises to their lives with weekly sessions.

introduction: the positive effects of physiotherapy and exercise on joint health, frequency of hemartrosis (foh) in patient with hemophilic arhropathy (pwha) are well explained in the literature. however, adaptation problems to physiotherapy sessions (usually 3 times a week) may cause pwha to ignore the need for therapy. it may be more beneficial for pwha to adapt physiotherapy and exercise into daily live. aim: to investigate the effect of a once-a-week physiotherapy combined with home exercises on joint health, foh, muscle strength, pain, reaction time and dynamic balance. methods: 20 patients have hemophilic arthropathy in knee and/or ankle were randomly divided into 2 groups, named home exercise (he) and comprehensive physiotherapy combined with home exercise (cpcwhe). in the clinical assessment, hjhs, manuel muscle tester, fitlight® system for reaction time, functional reach test for dynamic balance were used and questioned the number of bleedings in the last 6 weeks for foh. the cp group received comprehensive physiotherapy (manual therapy, neuromuscular electrical stimulation and exercises) 1 day a week, and did the exercises at home the other 2 days a week. the he group performed the exercises given to cp at home 3 times a week. evaluations were repeated at the end of 6 weeks.

Eligibility criteria:
inclusion criteria: -clinical diagnosis of hemophilia -clinical diagnosis of hemophilic arthropathy in ankle and/or exclusion criteria: * clinical diagnosis of any neurological disease

Keywords: hemophilia physiotherapy exercise reaction time joint health arthropathy
genomic study of relapse esophageal cancer after radiotherapy

Conditions: Gene Mutation-Related Cancer; Esophageal Cancer; Radiation Exposure

Summary: radiotherapy plays an important role in multidisciplinary treatment of esophageal cancer. however, about half patients received radiotherapy occurred relapse. once relapse occurred, there is no better treatment strategy. genomic study of relapsed esophageal cancer is seldom. so the investigators attempt to collect relapsed tissue to conduct with whole exome sequencing in order to investigate the genome landscape of recurrence esophageal cancer.

tumor tissue of patients received radiotherapy with diagnosis of recurrence between jan 1, 2010 and dec 1, 2020 were collected retrospectively. recurrence tumor tissue is collected between dec 31, 2020 and dec 31, 2022 prospectively. blood and preradiotherapy tumor tissue were also collected to be as contrast. a total of 100 paired blood, preradiotherapy tumor tissue and relapse tumor tissue were collected. what is more, a total of 100 paired blood and preradiotherapy tumor tissue with diagnosis of no recurrence were collected. all samples were conducted with whole exome sequencing. here the investigators define recurrence period as within 2 years and no recurrence period as more than 3 years after radiotherapy. criteria of relapse: (1) pathologic diagnosis is squamous carcinoma before radiotherapy;(2) received radiotherapy; (3)pathologic diagnosis is also squamous carcinoma after radiotherapy; (4) clinical symptoms including feeding obstruction etc; (5) imaging evidence showed disease progression.

Eligibility criteria:
inclusion criteria: 1. pathologic diagnosis is squamous cell carcinoma before radiotherapy; 2. pathologic diagnosis is squamous cell carcinoma after radiotherapy; 3. received radiotherapy 4. clinical symptoms including dysphagia, feeding obstruction, etc 5. image evidence showed disease progression 6. the period of recurrence was within 2 years after radiotherapy exclusion criteria: 1. pathologic diagnosis is not squamous cell carcinoma before radiotherapy; 2. pathologic diagnosis is not squamous cell carcinoma after radiotherapy 3. not received radiotherapy 4. the period of recurrence was more than 2 years after radiotherapy 5. the period of no recurrence was within 3 years after radiotherapy
a randomized controlled study of phacoemulsification by the enlarged internal incision and the regular 2.2mm incision

Conditions: Cataract

Summary: objective and principle: to evaluate whether enlarging the incision can reduce corneal complications associated with phacoemulsification with regular 2.2 mm incision. the aim of this study: to evaluate whether the technique of enlarging internal incision could reduce the incidence of descemet membrane detachment after 2.2 mm incision phacoemulsification. secondary outcome: to evaluate whether the technique of enlarged internal incision can reduce other corneal complications such as corneal edema and astigmatism after 2.2 mm incision phacoemulsification. study design: a prospective randomized controlled study


Eligibility criteria:
inclusion criteria: * age-related cataract patients * age from 65 to 90 * the diameter of pupil after mydriasis is more than 6 mm * locs iii nuclear grade ≥4 * corneal endothelial cell count \> 1500 cells/mm2 * phacoemulsification and intraocular lens implantation are planned * agree to participate in this study and sign informed consent exclusion criteria: * history of ocular trauma * anterior segment lesions (exfoliation syndrome, suspension ligament injury or relaxation, corneal and iris lesions, glaucoma) * other ocular diseases that impair visual function, such as optic neuropathy, uveitis and ocular tumors * history of ophthalmic surgery * intraoperative and postoperative complications
darbepoetin treatment of anemia in children with chronic renal failure

Conditions: Kidney Failure, Chronic

Summary: this is a study to determine the safety and effectiveness of darbepoetin (aranesp) given every 14 to 28 days to treat low red blood cells in children with chronic kidney failure.

erythropoietin (epo) is a glycoprotein synthesized in the kidneys which regulates the rate of proliferation and differentiation of red blood cell precursors. the main cause of anemia in children with chronic renal failure is deficiency of epo production as a result of declining renal function. recombinant human epo (rhuepo) is a synthetic erythropoietin that is structurally and functionally similar to naturally occuring epo. treatment of anemia using rhuepo has been associated with an improvement in the quality of life for patients, likely attributable to an increased production in hemoglobin and a reduction of dilatation of the heart. recently, an analogue of epo with two extra oligosaccharide chins, darbepoetin alfa, has been described as having a more prolonged effect requiring less frequent dosing. there are currently no data available on the efficacy of darbepoetin alfa administered every 14-28 days for children. the most common dosing schedules in the clinical trial at hsc are every 7, 10, and 14 days. due to reports of increased pain associated with the sc injection, and confusion of caregivers when the 10 day dosing schedule is necessary, the goals of the current proposal are to: 1) decrease the frequency of sc injections and 2)eliminate the 10 day dosing schedule for the administration of darbepoetin.

Eligibility criteria:
inclusion criteria: * diagnosis of chronic renal insufficiency or end stage renal disease (esrd) requiring dialysis * clinically stable * hemoglobin of 110-125 g/l in screening period; for naive subjects, hemoglobin \< 110 g/l * not iron deficient (tsat \> 19.5%) within 4 weeks of study entry * stable darbepoetin alpha therapy administered iv or sc q7 to q21 days or darbepoetin alpha naive * written informed consent from parent/legal guardian * less than 18 years old * weight at least 10 kg * females of childbearing potential must practice adequate contraception * availability for follow-up assessments exclusion criteria: * scheduled for a living donor kidney transplant within 12 weeks of signing consent * uncontrolled blood pressure as judged by principal investigator * change in seizure pattern in past 30 days; grand-mal seizure 12 weeks before enrollment * current clinical evidence of severe hyperparathyroidism * major surgery 2 weeks before signing consent * active inflammatory disease or condition requiring immunosuppressive therapy * currently receiving antibiotics for active systemic infection * peritoneal dialysis patient with an episode of peritonitis within the past 30 days * known hiv antibody positivity * known antibodies to rhuepo * known aluminum toxicity * known red cell aplasia * known malignancy

Keywords: chronic kidney failure darbepoetin pediatrics anemia
excimer laser for long length lesions in below-the-knee arteries study

Conditions: Peripheral Arterial Occlusive Disease

Summary: this investigation is designed to assess the immediate and long-term angiographic patency outcomes of excimer laser recanalisation followed by pta in the treatment of long (\>50 mm) infrapopliteal lesions in patients with critical limb ischemia (cli) the spectranetics turbo elite™ excimer laser catheters are percutaneous intravascular devices constructed of multiple optical fibers around a guidewire lumen. the laser catheters transmit ultraviolet energy from the spectranetics cvx-300® excimer laser system to the obstruction in the artery. the ultraviolet energy is delivered to the tip of the laser catheter to photo-ablate fibrous, calcific and atheromatous lesions, thus recanalizing diseased vessels.


Eligibility criteria:
inclusion criteria: * the treatment vessel is denovo * stenotic (\>50%) or occlusive atherosclerotic disease of infrapopliteal artery(s) * length of target lesion is \> 50 mm * reference target vessel diameter between 2-4.0 mm by visual assessment * documented rutherford class 4 or 5 symptomatic critical limb ischemia * the patient must be \>18 years of age * life-expectancy of more than 12 months * the patient has no child bearing potential or negative serum pregnancy test within 7 days of the index procedure * the patient must be willing and able to return to the appropriate follow-up times for the duration of the study * the patient must provide written patient informed consent that is approved by the ethics committee * anatomic inclusion criteria * all inflow lesions successfully (\<30 residual stenosis) treated prior to target lesion treatment during same procedure or according standard of care without unresolved complications * at least one angiographically visible target at the ankle for establishment of straight line flow. exclusion criteria: * patient refusing treatment * the target vessel segment diameter is not suitable for available catheter design. * unsuccessfully treated endovascular or bypass( \>30% residual stenosis) proximal ( iliac, sfa, popliteal) inflow limiting arterial/graft stenosis * lesion lies within or adjacent to an aneurysm * the patient has a known allergy to heparin, aspirin or other antiaggregant therapies or a bleeding diatheses or is unable, or unwilling, to tolerate such therapies. * the patient has a history of prior life-threatening contrast media reaction. * the patient is currently enrolled in another investigational device or drug trial. * the patient is currently breast-feeding, pregnant or intends to become pregnant. * the patient is unable to provide informed consent * the patient has end stage renal disease (currently on any form of dialysis) * known left ventricular ejection fraction \< 35% * the patient has had an mi within 30 days prior to enrollment * the patient has had a cva within 90 days prior to enrollment * serum creatinine \> 150 µmol * the patient has a previous bypass in the target limb * the patient has a current systemic infection

Keywords: cli excimer laser debulking